drugset / Trial / NCT02067416
PREDATOR: Neoadjuvant Gene Prediction for Breast Cancer
Phase 2
Withdrawn
Jenny C. Chang, MD
GE Healthcare · collabThe Methodist Hospital Research Institute · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
Study of the assay, Mammostrat®. to verify its utility as a predictor or outcome tool to determine whom would benefit from chemotherapy prior to surgery. Also could be used as a clinical marker to identify patients with breast cancer who do not benefit from some preoperative chemotherapies.
Timeline
- Start
- 2012-07
- Primary completion
- 2014-06
- Completion
- 2014-06
Outcome
Outcome not reported
Stopped (Business): “Funding agent withdrew funding”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Abraxane | Small molecule | — | — |
| Comparator | Docetaxel | Small molecule | — | — |
| Comparator | Doxorubicin | Other / unclassified | — | — |
| Comparator | Epirubicin | Small molecule | — | — |
| Comparator | Ixabepilone | Small molecule | — | — |
| Comparator | Paclitaxel | Small molecule | — | — |